Canada

Essa Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting

Lead Product(s): EPI-7386

Therapeutic Area: Oncology

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 15, 2020

Details:

In an oral poster presentation a more in-depth preclinical characterization of EPI-7386 including gene expression analyses and the toxicologic profile was presented.

Essa Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

ESSA Pharma Announces FDA Allowance of the Clinical Investigation of EPI-7386 in Prostate Cancer

Lead Product(s): EPI-7386

Therapeutic Area: Oncology

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 30, 2020

Details:

Phase 1 clinical trial will evaluate safety and tolerability of EPI-7386 for the treatment of metastatic castration-resistant prostate cancer.

Essa Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update

Lead Product(s): EPI-7386

Therapeutic Area: Oncology

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

Details:

ESSA Pharma has submitted an Investigational New Drug application to the U.S. FDA to evaluate its lead clinical candidate, EPI-7386, in a Phase 1 clinical study for the treatment of metastatic mCRPC.